Molecular Imaging Market Analysis
The Molecular Imaging Market size was valued at USD 8.47 billion in 2023 and is projected to grow steadily to USD 12.5 billion by 2032, expanding at a CAGR of 4.5% over the forecast period of 2024–2032. This growth is fueled by technological innovation, increasing chronic disease prevalence, and the global push for accurate, early-stage diagnostics.
Molecular imaging, a critical segment in diagnostic imaging, provides detailed visualization and measurement of biological processes at the molecular and cellular levels. With an increasing need for precision medicine and personalized care, molecular imaging systems such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) are gaining traction across healthcare systems worldwide.
Get a Free Sample Report of Molecular Imaging Market@ https://www.snsinsider.com/sample-request/5527
Growth Drivers Fueling Market Expansion
A key driver of the molecular imaging market is the rising incidence of chronic diseases. According to the World Health Organization (WHO), cancer was responsible for approximately 9.6 million deaths in 2020, making it one of the most pressing healthcare concerns globally. In the U.S., the National Cancer Institute estimates that nearly 39.5% of men and women will be diagnosed with cancer in their lifetime, creating a strong demand for early detection methods such as molecular imaging.
Additionally, aging populations are accelerating the demand for advanced imaging diagnostics. The United Nations forecasts that by 2050, one in every six people will be over the age of 65, up from one in eleven in 2019. As neurodegenerative diseases like Alzheimer’s become more common with age, molecular imaging plays a critical role in identifying early amyloid protein accumulations, leading to more effective intervention strategies.
Technological advancements also play a pivotal role. The integration of artificial intelligence (AI) in image analysis has significantly increased diagnostic accuracy and efficiency. Moreover, hybrid imaging systems and advanced radiotracers have enhanced the clarity, speed, and versatility of molecular diagnostics.
Government support for cancer research continues to strengthen the molecular imaging infrastructure. For instance, the U.S. National Institutes of Health allocated $6.9 billion to cancer research in FY 2021, while Horizon Europe committed €6.8 billion to health-related research, reinforcing public health policies that prioritize molecular diagnostics.
Market Segmentation Insights
By Modality
In 2023, SPECT dominated the molecular imaging modality segment, accounting for 42% of total market revenue. Its affordability and utility in diagnosing cardiovascular, oncological, and neurological conditions have made it the modality of choice in many healthcare settings. The development of cadmium zinc telluride (CZT) detectors has further improved SPECT’s efficiency and image quality, reinforcing its widespread clinical adoption.
By Application
Oncology emerged as the leading application segment with 32% market share in 2023. Molecular imaging, particularly PET-CT, is integral in detecting tumor activity, staging cancer, and monitoring therapy responses. The FDA’s approval of 68Ga-PSMA-11 for prostate cancer imaging represents a landmark in precision oncology, supporting the broader use of molecular imaging in cancer care.
By End Use
Hospitals captured 48% of the end-use segment in 2023. These institutions are often equipped with the capital and infrastructure needed to deploy advanced molecular imaging systems. The ability of hospitals to cater to complex cases, conduct clinical trials, and manage a high volume of patients contributes to their dominance in this segment.
Regional Overview
North America led the molecular imaging market in 2023 with a 43% revenue share, thanks to its robust healthcare infrastructure and rapid adoption of cutting-edge diagnostic technologies. In the U.S., total healthcare spending exceeded $4.1 trillion in 2020, creating a favorable environment for molecular imaging deployment. Regulatory agencies like the FDA have also expedited approvals of innovative imaging agents, promoting industry growth.
Meanwhile, the Asia-Pacific region is projected to experience the fastest market expansion during the forecast period. Rising healthcare investments, greater disease awareness, and technology adoption are accelerating growth in countries like China and India. Notably, China reported over 9,700 PET-CT scanners in operation by the end of 2020, highlighting the region’s expanding diagnostic capabilities.
Recent Developments
In June 2024, Positron Corporation announced the installation of its Attrius PET system by Q4 2024, offering enhanced nuclear cardiology imaging.
FUJIFILM India launched the APERTO Lucent open MRI, Arietta DeepInsight ultrasound series, and the FDX Visionary-DR bone scanner in February 2023, showcasing innovation in imaging hardware.
Market Challenges
Despite its vast potential, the molecular imaging market faces certain challenges. High capital investment, operational costs, and limited reimbursement policies continue to hinder adoption, particularly in developing and resource-constrained regions. Additionally, the complex handling of radiopharmaceuticals and the need for trained personnel further restrict market accessibility.
Buy a Single-User PDF of Molecular Imaging Market Analysis & Outlook Report 2024-5527@ https://www.snsinsider.com/checkout/5527
Key Players in the Molecular Imaging Ecosystem
GE Healthcare (Discovery MI, PET/CT Scanner)
Siemens Healthineers (Biograph mMR, Somatom PET-CT Scanner)
Philips Healthcare (Allegra PET/MR, PET/CT Scanner)
Canon Medical Systems Corporation (Vantage Galan 3T, Aquilion CT)
Medtronic, Thermo Fisher Scientific, PerkinElmer, Invivo, Hitachi Medical Systems, and Elekta AB
Major end-users include Mayo Clinic, MD Anderson Cancer Center, Stanford Health Care, and Kaiser Permanente.
Conclusion
The global molecular imaging market is poised for significant growth, driven by the rise in chronic diseases, aging populations, and rapid technological advancement. With increasing governmental and institutional investments, the market is expected to see robust demand in both developed and emerging economies. Strategic innovation, regulatory support, and cross-sector collaboration will be essential in overcoming current limitations and expanding access to life-saving molecular diagnostics.
Read Our Other Report
Chromatography Instruments Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
